Top > Search of International Patents > CELLULAR-DISORDER INHIBITOR, MEDICINAL COMPOSITION CONTAINING SAID CELLULAR-DISORDER INHIBITOR FOR PREVENTION OR TREATMENT OF ORGAN DERANGEMENT CAUSED BY HYPOXEMIA, AND MEDICINAL COMPOSITION CONTAINING SAID CELLULAR-DISORDER INHIBITOR FOR PREVENTION OR TREATMENT OF ISCHEMIC CEREBROVASCULAR DISORDER

CELLULAR-DISORDER INHIBITOR, MEDICINAL COMPOSITION CONTAINING SAID CELLULAR-DISORDER INHIBITOR FOR PREVENTION OR TREATMENT OF ORGAN DERANGEMENT CAUSED BY HYPOXEMIA, AND MEDICINAL COMPOSITION CONTAINING SAID CELLULAR-DISORDER INHIBITOR FOR PREVENTION OR TREATMENT OF ISCHEMIC CEREBROVASCULAR DISORDER

Foreign code F160008792
File No. (S2014-1592-N0,S2015-0263-N0)
Posted date Aug 4, 2016
Country WIPO
International application number 2015JP079023
International publication number WO 2016060158
Date of international filing Oct 14, 2015
Date of international publication Apr 21, 2016
Priority data
  • P2014-212064 (Oct 16, 2014) JP
  • P2015-029698 (Feb 18, 2015) JP
Title CELLULAR-DISORDER INHIBITOR, MEDICINAL COMPOSITION CONTAINING SAID CELLULAR-DISORDER INHIBITOR FOR PREVENTION OR TREATMENT OF ORGAN DERANGEMENT CAUSED BY HYPOXEMIA, AND MEDICINAL COMPOSITION CONTAINING SAID CELLULAR-DISORDER INHIBITOR FOR PREVENTION OR TREATMENT OF ISCHEMIC CEREBROVASCULAR DISORDER
Abstract The present invention is a cellular-disorder inhibitor characterized by containing any one of peptides (a) to (g), a derivative thereof, or a salt or ester of these as an active ingredient.
Outline of related art and contending technology BACKGROUND ART
Hemostatic coagulation factor 9 (F9) is involved in clotting, blood coagulation factors of the long-known and essential fatty acid, a protein known as the cause of hemophilia. F9 Is, in the course of the blood coagulation reaction, clotting factors and clotting factors (F11) 11 (F7) by 7, present between the light and heavy chains of an intermediate portion (Activation peptide (hereinafter, also referred to as F9-AP.) ) Is cut off, is activated. The cut F9-AP is also light and heavy chains connected by a disulfide bond and, as a single molecule of 1 to promote blood coagulation reaction. However, the function of the reports F9-AP not.
The present inventors, extension of the cell and cause F9-AP revealed, epithelial and endothelial damage was found to be effective as a therapeutic agent (see Patent Document 1).
However, a variety of causes, cell, organ, sufficient oxygen is not supplied to the tissue, cell, organ, subject to tissue is disturbed. Cell, organ, tissue sufficient oxygen is supplied as in the non-, a poorly water-soluble accident, disaster, asphyxiation, anesthesia accident hypoxemia; pneumonia, respiratory diseases and bronchial asthma; shock, myocardial infarction, disseminated intravascular coagulation syndrome such as impaired blood flow by organ failure and the like. Such hypoxia induced by impairment of organs such as methods of treatment include, hypothermia treatment method can be used (see non-patent document 1-2).
In addition, causes the death of as Japanese, stroke is a cancer, heart disease, pneumonia 4 then serving as the first. However, the first stroke is the heart of a lying to persist or site of 1, compared with the incidence of myocardial infarction, stroke and the incidence rate of 3-10 times, in regard to the prophylaxis and treatment of stroke is important is in the absence of undoubtedly. Stroke about 12 million deaths a year and, according to the cerebral infarction is 60%. Cerebral infarction exact incidence is unknown, roughly one million 100-200 population in 10, 40 and 10 before and after 600 years of age or older is estimated to be one million. Rapid super senior population in regard to advances, the incidence of cerebral infarction, cerebral infarction total number of patients, the number of fatalities due to cerebral infarction, the number of the person, is increasingly expected to increase. Currently, the most effective treatment of thrombolytic therapy is cerebral infarction. Recombinant tissue plasminogen activator (rt-PA, alteplase) intravenous administration of 4.5 that can be treated within one hour from the onset of ischemic cerebral vascular disease in a patient who has been determined to be carefully adapted to strongly recommended (see non-patent document 3-4). In addition, edaravone is expected brain protective effect for cerebral infarction (thrombosis, embolism) recommended as a method of treating a patient (see non-patent document 5).
Scope of claims (In Japanese)[請求項1]
以下の(a)~(g)のいずれかのペプチド、その誘導体、又はこれらの塩若しくはエステルを有効成分として含有することを特徴とする細胞障害抑制剤。
(a)配列番号2、5~10、17のいずれかに示すアミノ酸配列を含むペプチド、
(b)配列番号4、11~16、18のいずれかに示すアミノ酸配列を含むペプチド、
(c)配列番号2、5~10、17のいずれかに示すアミノ酸配列において、1若しくは数個のアミノ酸が欠失、置換若しくは付加されたアミノ酸配列を含み、かつ、細胞障害抑制能を有するペプチド、
(d)配列番号4、11~16、18のいずれかに示すアミノ酸配列において、1若しくは数個のアミノ酸が欠失、置換若しくは付加されたアミノ酸配列を含み、かつ、細胞障害抑制能を有するペプチド、
(e)配列番号2、5~10、17のいずれかに示すアミノ酸配列と同一性が70%以上であるアミノ酸配列を含み、かつ、細胞障害抑制能を有するペプチド、
(f)配列番号4、11~16、18のいずれかに示すアミノ酸配列と同一性が70%以上であるアミノ酸配列を含み、かつ、細胞障害抑制能を有するペプチド、
(g)(a)~(f)のいずれかの断片であって、かつ、細胞障害抑制能を有するペプチド。
[請求項2]
前記細胞障害抑制能が低酸素により誘導される細胞障害に対する抑制能である、請求項1に記載の細胞障害抑制剤。
[請求項3]
請求項1又は2に記載の細胞障害抑制剤、並びに薬学的に許容できる担体及び希釈剤のうち少なくともいずれかを含むことを特徴とする低酸素血症によって生じる臓器障害の予防又は治療用医薬組成物。
[請求項4]
請求項1に記載の細胞障害抑制剤、並びに薬学的に許容できる担体及び希釈剤のうち少なくともいずれかを含むことを特徴とする虚血性脳血管障害の予防又は治療用医薬組成物。
[請求項5]
1回の投与におけるペプチドの含有量が、1kg体重当たり0.1mg以上である請求項4に記載の虚血性脳血管障害の予防又は治療用医薬組成物。
[請求項6]
1回の投与におけるペプチドの含有量が、1kg体重当たり0.4mg以上1mg以下である請求項4に記載の虚血性脳血管障害の予防又は治療用医薬組成物。
[請求項7]
虚血性脳血管障害の発症後、8時間以内に投与される請求項4~6のいずれか一項に記載の虚血性脳血管障害の予防又は治療用医薬組成物。
[請求項8]
虚血性脳血管障害の発症後、7時間以内に投与される請求項4~7のいずれか一項に記載の虚血性脳血管障害の予防又は治療用医薬組成物。
[請求項9]
虚血性脳血管障害の発症後、6時間以内に投与される請求項4~8のいずれか一項に記載の虚血性脳血管障害の予防又は治療用医薬組成物。
[請求項10]
血栓溶解療法と併用して用いられることを特徴とする請求項7~9のいずれか一項に記載の虚血性脳血管障害の予防又は治療用医薬組成物。
  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • NIHON UNIVERSITY
  • Inventor
  • HIDAI Chiaki
  • MASUKO Takashi
  • KITANO Hisataka
  • MAMIYA Atsushi
IPC(International Patent Classification)
Specified countries National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
Please contact us by E-mail or facsimile if you have any interests on this patent.

PAGE TOP

close
close
close
close
close
close